Skip to main content
Top
Published in: Annals of Hematology 6/2008

Open Access 01-06-2008 | Original article

Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature

Authors: M. de Fost, T. A. Out, F. A. de Wilde, E. P. M. Tjin, S. T. Pals, M. H. J. van Oers, R. G. Boot, J. F. M. G. Aerts, M. Maas, S. vom Dahl, C. E. M. Hollak

Published in: Annals of Hematology | Issue 6/2008

Login to get access

Abstract

Gaucher disease type I, the most common lysosomal storage disorder, is associated with immunoglobulin abnormalities. We studied the prevalence, risk factors, pathogenesis, and effect of enzyme relation therapy (ERT) on gammopathies in an adult Gaucher disease type I cohort (N = 63) and related the results to a review of the currently available literature. Polyclonal gammopathies and monoclonal gammopathy of undetermined significance (MGUS) in our adult GD I cohort were found in 41% and 19% of patients. These results are similar to the data from the literature and correspond to the increased risk of multiple myeloma (MM) that has been described. The prevalence of MGUS in our cohort increased with age but was not associated with disease severity or exposure time. The serum levels of free light chains of immunoglobulins were measured and were not found predictive for the development of MGUS or MM. Levels of pro- as well as anti-inflammatory cytokines, growth factors, and chemokines, especially those involved in inflammation and B-cell function, are disturbed in GD I, with the most impressive and consisting elevations for interleukin-10 and pulmonary and activation-regulated chemokine. A beneficial effect of ERT on the occurrence and progression of gammopathies was suggested from longitudinal data.
Literature
1.
go back to reference Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 18:221–225PubMedCrossRef Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher’s disease. Biochem Biophys Res Commun 18:221–225PubMedCrossRef
2.
go back to reference Patrick AD (1965) Short communications: a deficiency of glucocerebrosidase in Gaucher’s disease. Biochem J 97:17C–18C Patrick AD (1965) Short communications: a deficiency of glucocerebrosidase in Gaucher’s disease. Biochem J 97:17C–18C
3.
go back to reference Airo R, Gabusi G, Guindani M (1993) Gaucher’s disease associated with monoclonal gammopathy of undetermined significance: a case report. Haematologica 78:129–131PubMed Airo R, Gabusi G, Guindani M (1993) Gaucher’s disease associated with monoclonal gammopathy of undetermined significance: a case report. Haematologica 78:129–131PubMed
4.
go back to reference Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. QJM 90:19–25PubMed Allen MJ, Myer BJ, Khokher AM, Rushton N, Cox TM (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. QJM 90:19–25PubMed
5.
go back to reference Benjamin D, Joshua H, Djaldetti M, Hazaz B, Pinkhas J (1979) Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher’s disease. Scand J Haematol 22:179–184PubMedCrossRef Benjamin D, Joshua H, Djaldetti M, Hazaz B, Pinkhas J (1979) Nonsecretory IgD-kappa multiple myeloma in a patient with Gaucher’s disease. Scand J Haematol 22:179–184PubMedCrossRef
6.
go back to reference Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A (2004) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 32:214–217PubMedCrossRef Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A (2004) Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Blood Cells Mol Dis 32:214–217PubMedCrossRef
7.
go back to reference Chang-Lo M, Yam LT, Rubenstone AI, Schwartz SO (1975) Gaucher’s disease associated with chronic lymphocytic leukaemia, gout and carcinoma. J Pathol 116:203–207PubMedCrossRef Chang-Lo M, Yam LT, Rubenstone AI, Schwartz SO (1975) Gaucher’s disease associated with chronic lymphocytic leukaemia, gout and carcinoma. J Pathol 116:203–207PubMedCrossRef
8.
go back to reference Dikman SH, Goldstein M, Kahn T, Leo MA, Weinreb N (1978) Amyloidosis. An unusual complication of Gaucher’s disease. Arch Pathol Lab Med 102:460–462PubMed Dikman SH, Goldstein M, Kahn T, Leo MA, Weinreb N (1978) Amyloidosis. An unusual complication of Gaucher’s disease. Arch Pathol Lab Med 102:460–462PubMed
9.
go back to reference Fox H, McCarthy P, Andre-Schwartz J, Shoenfeld Y, Miller KB (1984) Gaucher’s disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher’s disease and B-cell proliferations? Cancer 54:312–314PubMedCrossRef Fox H, McCarthy P, Andre-Schwartz J, Shoenfeld Y, Miller KB (1984) Gaucher’s disease and chronic lymphocytic leukemia. Possible pathogenetic link between Gaucher’s disease and B-cell proliferations? Cancer 54:312–314PubMedCrossRef
10.
go back to reference Garfinkel D, Sidi Y, Ben Bassat M et al (1982) Coexistence of Gaucher’s disease and multiple myeloma. Arch Intern Med 142:2229–2230PubMedCrossRef Garfinkel D, Sidi Y, Ben Bassat M et al (1982) Coexistence of Gaucher’s disease and multiple myeloma. Arch Intern Med 142:2229–2230PubMedCrossRef
11.
go back to reference Hanash SM, Rucknagel DL, Heidelberger KP, Radin NS (1978) Primary amyloidosis associated with Gaucher’s disease. Ann Intern Med 89:639–641PubMed Hanash SM, Rucknagel DL, Heidelberger KP, Radin NS (1978) Primary amyloidosis associated with Gaucher’s disease. Ann Intern Med 89:639–641PubMed
12.
go back to reference Harder H, Eucker J, Zang C et al (2000) Coincidence of Gaucher’s disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence–Jones proteinuria. Ann Hematol 79:640–643PubMedCrossRef Harder H, Eucker J, Zang C et al (2000) Coincidence of Gaucher’s disease due to a 1226G/1448C mutation and of an immunoglobulin G lambda multiple myeloma with Bence–Jones proteinuria. Ann Hematol 79:640–643PubMedCrossRef
13.
go back to reference Hrebicek M, Zeman J, Musilova J et al (1996) A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Virchows Arch 429:305–309PubMedCrossRef Hrebicek M, Zeman J, Musilova J et al (1996) A case of type I Gaucher disease with cardiopulmonary amyloidosis and chitotriosidase deficiency. Virchows Arch 429:305–309PubMedCrossRef
14.
go back to reference Kaloterakis A, Filiotou A, Koskinas J et al (1999) Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. J Intern Med 246:587–590PubMedCrossRef Kaloterakis A, Filiotou A, Koskinas J et al (1999) Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. J Intern Med 246:587–590PubMedCrossRef
15.
go back to reference Mark T, Dominguez C, Rywlin AM (1982) Gaucher’s disease associated with chronic lymphocytic leukemia. South Med J 75:361–363PubMed Mark T, Dominguez C, Rywlin AM (1982) Gaucher’s disease associated with chronic lymphocytic leukemia. South Med J 75:361–363PubMed
16.
go back to reference Marti GE, Ryan ET, Papadopoulos NM et al (1988) Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 29:189–194PubMedCrossRef Marti GE, Ryan ET, Papadopoulos NM et al (1988) Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Am J Hematol 29:189–194PubMedCrossRef
17.
go back to reference Petrides PE, leCoutre P, Muller-Hocker J et al (1998) Coincidence of Gaucher’s disease due to a private mutation and Ph′ positive chronic myeloid leukemia. Am J Hematol 59:87–90PubMedCrossRef Petrides PE, leCoutre P, Muller-Hocker J et al (1998) Coincidence of Gaucher’s disease due to a private mutation and Ph′ positive chronic myeloid leukemia. Am J Hematol 59:87–90PubMedCrossRef
18.
go back to reference Pinkhas J, Djaldetti M, Yaron M (1965) Coincidence of multiple myeloma with Gaucher’s disease. Isr J Med Sci 1:537–540PubMed Pinkhas J, Djaldetti M, Yaron M (1965) Coincidence of multiple myeloma with Gaucher’s disease. Isr J Med Sci 1:537–540PubMed
19.
go back to reference Pratt PW, Kochwa S, Estren S (1968) Immunoglobulin abnormalities in Gaucher’s disease. Report of 16 cases. Blood 31:633–640PubMed Pratt PW, Kochwa S, Estren S (1968) Immunoglobulin abnormalities in Gaucher’s disease. Report of 16 cases. Blood 31:633–640PubMed
20.
go back to reference Ruestow PC, Levinson DJ, Catchatourian R et al (1980) Coexistence of IgA myeloma and Gaucher’s disease. Arch Intern Med 140:1115–1116PubMedCrossRef Ruestow PC, Levinson DJ, Catchatourian R et al (1980) Coexistence of IgA myeloma and Gaucher’s disease. Arch Intern Med 140:1115–1116PubMedCrossRef
21.
go back to reference Shoenfeld Y, Gallant LA, Shaklai M et al (1982) Gaucher’s disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106:388–391PubMed Shoenfeld Y, Gallant LA, Shaklai M et al (1982) Gaucher’s disease: a disease with chronic stimulation of the immune system. Arch Pathol Lab Med 106:388–391PubMed
22.
go back to reference Turesson I, Rausing A (1975) Gaucher’s disease and benign monoclonal gammopathy. A case report with immunofluorescence study of bone marrow and spleen. Acta Med Scand 197:507–512PubMedCrossRef Turesson I, Rausing A (1975) Gaucher’s disease and benign monoclonal gammopathy. A case report with immunofluorescence study of bone marrow and spleen. Acta Med Scand 197:507–512PubMedCrossRef
23.
go back to reference Dispenzieri A, Gertz MA, Therneau TM, Kyle RA (2001) Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 76:476–487PubMed Dispenzieri A, Gertz MA, Therneau TM, Kyle RA (2001) Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc 76:476–487PubMed
24.
go back to reference Kyle RA, Therneau TM, Rajkumar SV et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369PubMedCrossRef Kyle RA, Therneau TM, Rajkumar SV et al (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362–1369PubMedCrossRef
25.
go back to reference Lee RE (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95:177–217PubMed Lee RE (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95:177–217PubMed
26.
go back to reference de Fost M, Vom DS, Weverling GJ et al (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36:53–58PubMedCrossRef de Fost M, Vom DS, Weverling GJ et al (2006) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36:53–58PubMedCrossRef
27.
go back to reference Rosenbloom BE, Weinreb NJ, Zimran A et al (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105:4569–4572PubMedCrossRef Rosenbloom BE, Weinreb NJ, Zimran A et al (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105:4569–4572PubMedCrossRef
28.
go back to reference Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72:219–224PubMedCrossRef Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72:219–224PubMedCrossRef
29.
go back to reference Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200PubMedCrossRef Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34:197–200PubMedCrossRef
30.
go back to reference Barak V, Acker M, Nisman B et al (1999) Cytokines in Gaucher’s disease. Eur Cytokine Netw 10:205–210PubMed Barak V, Acker M, Nisman B et al (1999) Cytokines in Gaucher’s disease. Eur Cytokine Netw 10:205–210PubMed
31.
go back to reference Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201–212PubMedCrossRef Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 23:201–212PubMedCrossRef
32.
go back to reference Lichtenstein M, Zimran A, Horowitz M (1997) Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 23:395–401PubMedCrossRef Lichtenstein M, Zimran A, Horowitz M (1997) Cytokine mRNA in Gaucher disease. Blood Cells Mol Dis 23:395–401PubMedCrossRef
33.
go back to reference Michelakakis H, Spanou C, Kondyli A et al (1996) Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317:219–222PubMed Michelakakis H, Spanou C, Kondyli A et al (1996) Plasma tumor necrosis factor-a (TNF-a) levels in Gaucher disease. Biochim Biophys Acta 1317:219–222PubMed
34.
go back to reference Borset M, Lien E, Espevik T et al (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271:24655–24661PubMedCrossRef Borset M, Lien E, Espevik T et al (1996) Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 271:24655–24661PubMedCrossRef
35.
go back to reference Boot RG, Verhoek M, de Fost M et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33–39PubMedCrossRef Boot RG, Verhoek M, de Fost M et al (2004) Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 103:33–39PubMedCrossRef
36.
go back to reference Deibener J, Kaminsky P, Jacob C et al (1998) Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher’s disease. Haematologica 83:479–480PubMed Deibener J, Kaminsky P, Jacob C et al (1998) Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher’s disease. Haematologica 83:479–480PubMed
37.
go back to reference Bradwell AR, Carr-Smith HD, Mead GP et al (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673–680PubMed Bradwell AR, Carr-Smith HD, Mead GP et al (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 47:673–680PubMed
38.
go back to reference Drayson M, Tang LX, Drew R et al (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900–2902PubMedCrossRef Drayson M, Tang LX, Drew R et al (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 97:2900–2902PubMedCrossRef
39.
go back to reference Katzmann JA, Clark RJ, Abraham RS et al (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437–1444PubMed Katzmann JA, Clark RJ, Abraham RS et al (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 48:1437–1444PubMed
40.
go back to reference Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51:878–881PubMedCrossRef Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA (2005) Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 51:878–881PubMedCrossRef
41.
go back to reference Rajkumar SV, Kyle RA, Therneau TM et al (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812–817PubMedCrossRef Rajkumar SV, Kyle RA, Therneau TM et al (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812–817PubMedCrossRef
42.
go back to reference Abadie JM, Bankson DD (2006) Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci 36:157–162PubMed Abadie JM, Bankson DD (2006) Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci 36:157–162PubMed
43.
go back to reference Daniels LB, Glew RH (1982) beta-Glucosidase assays in the diagnosis of Gaucher’s disease. Clin Chem 28:569–577PubMed Daniels LB, Glew RH (1982) beta-Glucosidase assays in the diagnosis of Gaucher’s disease. Clin Chem 28:569–577PubMed
44.
go back to reference Hollak CE, Aerts JM, Goudsmit R et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher’s disease. Lancet 345:1474–1478PubMedCrossRef Hollak CE, Aerts JM, Goudsmit R et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher’s disease. Lancet 345:1474–1478PubMedCrossRef
45.
go back to reference Zimran A, Kay A, Gelbart T et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71:337–353 Zimran A, Kay A, Gelbart T et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71:337–353
46.
go back to reference Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757
47.
go back to reference Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRef Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedCrossRef
48.
go back to reference Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRef Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420PubMedCrossRef
49.
go back to reference Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292PubMedCrossRef Hollak CE, van Weely S, van Oers MH, Aerts JM (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93:1288–1292PubMedCrossRef
50.
go back to reference Grosbois B, Jego P, de Rosa H et al (1997) Triclonal gammopathy and malignant immunoproliferative syndrome. Rev Med Interne 18:470–473PubMed Grosbois B, Jego P, de Rosa H et al (1997) Triclonal gammopathy and malignant immunoproliferative syndrome. Rev Med Interne 18:470–473PubMed
51.
go back to reference Hughes D, Cappellini MD, Berger M et al (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138(6):676–686PubMedCrossRef Hughes D, Cappellini MD, Berger M et al (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138(6):676–686PubMedCrossRef
52.
go back to reference Altarescu G, Phillips M, Foldes AJ et al (2003) The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene? QJM 96:575–578PubMedCrossRef Altarescu G, Phillips M, Foldes AJ et al (2003) The interleukin-6 promoter polymorphism in Gaucher disease: a new modifier gene? QJM 96:575–578PubMedCrossRef
53.
go back to reference Gery I, Zigler JS Jr., Brady RO, Barranger JA (1981) Selective effects of glucocerebroside (Gaucher’s storage material) on macrophage cultures. J Clin Invest 68:1182–1189PubMedCrossRef Gery I, Zigler JS Jr., Brady RO, Barranger JA (1981) Selective effects of glucocerebroside (Gaucher’s storage material) on macrophage cultures. J Clin Invest 68:1182–1189PubMedCrossRef
54.
go back to reference Mizukami H, Mi Y, Wada R et al (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 109:1215–1221PubMed Mizukami H, Mi Y, Wada R et al (2002) Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 109:1215–1221PubMed
55.
go back to reference Boven LA, van Meurs M, Boot RG et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359–369PubMedCrossRef Boven LA, van Meurs M, Boot RG et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122:359–369PubMedCrossRef
56.
go back to reference Altarescu G, Zimran A, Michelakakis H, Elstein D (2005) TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 31:149–152PubMedCrossRef Altarescu G, Zimran A, Michelakakis H, Elstein D (2005) TNF-alpha levels and TNF-alpha gene polymorphism in type I Gaucher disease. Cytokine 31:149–152PubMedCrossRef
Metadata
Title
Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature
Authors
M. de Fost
T. A. Out
F. A. de Wilde
E. P. M. Tjin
S. T. Pals
M. H. J. van Oers
R. G. Boot
J. F. M. G. Aerts
M. Maas
S. vom Dahl
C. E. M. Hollak
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 6/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0441-8

Other articles of this Issue 6/2008

Annals of Hematology 6/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.